1.Blood coagulation disorders caused by cefmenoxime in a patient with renal failure and pancreatitis
Chunsheng YANG ; Yumei MENG ; Wenyong JIANG ; Hongna WANG ; Jinshan LIANG ; Yanmei LIU ; Chunna KAN ; Xueliang ZHU ; Yu LIU ; Jianpeng YU
Adverse Drug Reactions Journal 2021;23(5):279-280
A 65-year-old female patient with chronic renal failure undergoing continuous hemodialysis received an IV infusion of cefmenoxime 1 g twice daily for acute pancreatitis. The values of prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (APTT) were within the normal range before treatment. After 11 days of treatment, the patient developed multiple ecchymoses on the skin and bleeding from the venipuncture site which was not easily stopped. The reexamination of coagulation function showed PT 127 s, INR 10.72, and APTT 86 s. Coagulation dysfunction was considered and an IV infusion of leukocyte-reduced fresh-frozen plasma 150 ml was given. Examination of coagulation function next day showed PT 101 s, INR 8.49, and APTT 65 s. Mixing study for evaluation of abnormal coagulation testing showed that PT and APTT could be corrected, suggesting coagulation factor deficiency. Blood coagulation disorders caused by cefmenoxime was considered. Then the drug was discontinued and switched to amoxicillin sodium and clavulanate potassium, and a subcutaneous injection of vitamin K 1 10 mg was given once daily. Three days after the drug withdrawal, her coagulation function returned to within the normal range (PT 15 s, INR 1.19, APTT 36 s).
2.Blood coagulation disorders caused by cefmenoxime in a patient with renal failure and pancreatitis
Chunsheng YANG ; Yumei MENG ; Wenyong JIANG ; Hongna WANG ; Jinshan LIANG ; Yanmei LIU ; Chunna KAN ; Xueliang ZHU ; Yu LIU ; Jianpeng YU
Adverse Drug Reactions Journal 2021;23(5):279-280
A 65-year-old female patient with chronic renal failure undergoing continuous hemodialysis received an IV infusion of cefmenoxime 1 g twice daily for acute pancreatitis. The values of prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (APTT) were within the normal range before treatment. After 11 days of treatment, the patient developed multiple ecchymoses on the skin and bleeding from the venipuncture site which was not easily stopped. The reexamination of coagulation function showed PT 127 s, INR 10.72, and APTT 86 s. Coagulation dysfunction was considered and an IV infusion of leukocyte-reduced fresh-frozen plasma 150 ml was given. Examination of coagulation function next day showed PT 101 s, INR 8.49, and APTT 65 s. Mixing study for evaluation of abnormal coagulation testing showed that PT and APTT could be corrected, suggesting coagulation factor deficiency. Blood coagulation disorders caused by cefmenoxime was considered. Then the drug was discontinued and switched to amoxicillin sodium and clavulanate potassium, and a subcutaneous injection of vitamin K 1 10 mg was given once daily. Three days after the drug withdrawal, her coagulation function returned to within the normal range (PT 15 s, INR 1.19, APTT 36 s).

Result Analysis
Print
Save
E-mail